Multiple Sclerosis (MS)

Multiple Sclerosis (MS) involves communication problems between the brain and the rest of the body due to immune attacks on axons and myelin in the central nervous system. Below are COVID news and research updates that specifically relate to MS.

Risk of Relapse is Low for MS patients After COVID Vaccination, Study Finds

Research published in the Journal of Neurology, Neurosurgery, and Psychiatry has indicated that multiple sclerosis (MS) patients did not see a rise in symptoms following COVID-19 vaccination with the Pfizer vaccine. Cohort characteristics included 93.5% of patients having relapsing-remitting MS, 4.6% having secondary progressive disease, and 1.9% having primary progressive disease.

Read More »

~89% of Those with Chronic Inflammatory Conditions Produce Antibodies Following Vaccination, Despite Immunosuppressant Usage

The Washington University School of Medicine is conducting a study called COVaRiPAD (COVID-19 Vaccine Responses in Patients with Autoimmune Disease). The team just published research looking at the effect of immunosuppression on the efficacy of mRNA COVID-19 vaccines. They found that 88.7% of patients with chronic inflammatory conditions* (CID), including rheumatoid arthritis (28.5%), Crohn’s disease (16.5%), spondyloarthritis (15%), ulcerative colitis (13.5%), systemic lupus erythematosus (11.3%), multiple sclerosis (6.8%), and sjögrens syndrome (6%), produced detectable antibodies in response to the vaccine.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.